Talphera TLPH
NASDAQ TLPH
$1.24 +0.02 (+1.64%)
At close: Sep 10, 2026 · 4:00 PM EDT

Talphera (TLPH) Net Equity Issued and Repurchased (2011 - 2023)

Talphera (TLPH) posted Net Equity Issued and Repurchased of -$8.9 million for Q4 2023, down 4562.0% on a QoQ basis from $200000.0 in Q3 2022.

Analysis

Talphera (TLPH) Net Equity Issued and Repurchased (2011 - 2023) Analysis & Trends

Talphera has reported Net Equity Issued and Repurchased for 9 years, with the latest figure at -$8.9 million in Q4 2023.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$8.9 million in Q4 2023; TTM through Dec 2024 was -$8.7 million, a 0.0% change from a year earlier, with the FY2022 full-year figure at $239000.0, changed N/A from the prior year.
  • Net Equity Issued and Repurchased was -$8.9 million for Q4 2023 at Talphera, down from $200000.0 in the prior quarter.
  • The five-year high for Net Equity Issued and Repurchased was $36.4 million in Q1 2021, with the low at -$36.4 million in Q4 2021.
  • Average Net Equity Issued and Repurchased over 5 years is $2.1 million, with a median of $1.0 million recorded in 2019.
  • The largest YoY upside for Net Equity Issued and Repurchased was 4537.76% in 2021 against a maximum downside of 465.91% in 2021.
  • Over 5 years, Net Equity Issued and Repurchased stood at $1.2 million in 2019, then surged by 705.92% to $9.9 million in 2020, then sank by 465.91% to -$36.4 million in 2021, then jumped by 100.55% to $200000.0 in 2022, then plunged by 4562.0% to -$8.9 million in 2023.
  • The last three Net Equity Issued and Repurchased figures came in at -$8.9 million (Q4 2023), $200000.0 (Q3 2022), and -$36.4 million (Q4 2021), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn -
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 9.00 Mn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 49.20 Mn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn -
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn -
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 Talphera 92.90 Mn 92.90 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -8.92 Mn
Sep 30, 2022 200,000.00
Dec 31, 2021 -36.36 Mn
Jun 30, 2021 7.50 Mn
Mar 31, 2021 36.36 Mn
Dec 31, 2020 9.94 Mn
Sep 30, 2020 9.95 Mn
Jun 30, 2020 665,000.00
Mar 31, 2020 784,000.00
Sep 30, 2019 1.23 Mn
Dec 31, 2018 52.45 Mn
Sep 30, 2018 21.67 Mn
Sep 30, 2013 1.25 Mn
Mar 31, 2013 84,000.00
Sep 30, 2012 55,000.00
Jun 30, 2012 19,000.00
Mar 31, 2012 89,000.00
Dec 31, 2011 -3,000.00
Sep 30, 2011 146,000.00